FDA Approves Novartis' Rhapsido (remibrutinib) as First Treatment for Symptomatic Dermographism

Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Rhapsido (remibrutinib) as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines. This approval marks a significant advancement for individuals experiencing chronic hives and itch triggered by skin friction.